Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
209 studies found for:    "Hemorrhagic fever"
Show Display Options
Rank Status Study
1 Enrolling by invitation Treatment of Viral Hemorrhagic Fevers With Intravenous Ribavirin in Military Treatment Facilities
Conditions: Crimean-Congo Hemorrhagic Fever;   Lassa Fever
Intervention: Drug: Ribavirin (Virazole) Injection
2 Enrolling by invitation Ribavirin for Hemorrhagic Fever With Renal Syndrome
Condition: Hemorrhagic Fever With Renal Syndrome
Intervention: Drug: Ribavirin
3 Enrolling by invitation Ribavirin for Hemorrhagic Fever With Renal Syndrome in Germany
Condition: Hemorrhagic Fever With Renal Syndrome
Intervention: Drug: Virazole (Ribavirin)
4 Recruiting Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
Condition: Hemorrhagic Fever With Renal Syndrome
Interventions: Biological: HTNV/PUUV DNA vaccine;   Biological: Placebo
5 Not yet recruiting Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
Condition: Viral Hemorrhagic Fever
Intervention: Drug: Ribavirin
6 Completed Study to Evaluate the Safety, Tolerability, and Immunogenicity of Hantaan and Puumala Virus DNA Vaccines
Condition: Hemorrhagic Fever With Renal Syndrome
Intervention: Biological: Vaccine/device combination for prevention of HFRS
7 Active, not recruiting Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: cAd3-EBOZ;   Biological: cAd3-EBO;   Biological: MVA-EbolaZ
8 Recruiting Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo
9 Recruiting Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
10 Recruiting Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
11 Completed Experimental Ebola Vaccine Trial
Conditions: Hemorrhagic Fever, Ebola;   Healthy
Intervention: Drug: VRC-EBODNA012-00-VP
12 Completed Experimental Vaccine for Prevention of Ebola Virus Infection
Conditions: Ebola Hemorrhagic Fever;   Ebola Virus Disease;   Ebola Virus Vaccines;   Envelope Glycoprotein, Ebola Virus;   Filovirus
Intervention: Drug: VRC-EBOADV018-00-VP
13 Completed Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever
Conditions: Acquired Bleeding Disorder;   Dengue Haemorrhagic Fever
Interventions: Drug: activated recombinant human factor VII;   Drug: placebo
14 Not yet recruiting Open Study of the Duration of Immunity After Vaccination With GamEvac
Condition: Ebola Hemorrhagic Fever
Intervention: Procedure: blood sampling collection
15 Not yet recruiting Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi
Condition: Ebola Hemorrhagic Fever
Intervention: Procedure: blood sampling collection
16 Recruiting Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: CYD Dengue Vaccine (5 dose formulation);   Biological: Placebo, NaCl 0.9%
17 Not yet recruiting Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever;   Human Immunodeficiency Virus
Interventions: Biological: CYD Dengue Vaccine;   Biological: Placebo (NaCl 0.9%) vaccine group
18 Active, not recruiting Immunogenicity and Safety of 3-Dose and Booster Dose of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: CYD Dengue Vaccine;   Biological: NaCl + CYD Dengue Vaccine
19 Recruiting Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: CYD Dengue Vaccine (5-dose formulation);   Biological: Placebo, NaCl 0.9%
20 Completed Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
Conditions: Dengue;   Dengue Fever;   Dengue Hemorrhagic Fever
Intervention:

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years